Proprotein convertase subtilisin/kexin type 9 inhibitors are not currently cost effective for the prevention of cardiovascular events in patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, US research shows.
There is insufficient evidence to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents, concludes a recommendation statement from the US Preventive Services Task Force.
Pooled data from the ODYSSEY phase III trials show that PCSK9 inhibition does not result in excess cases of new-onset diabetes during up to 18 months of treatment, despite mounting evidence that lowering cholesterol levels increases diabetes risk.
Findings from a Mendelian randomisation study suggest that lifelong exposure to increased levels of the major lipid fractions is protective against Type 2 diabetes, even as it raises the risk of coronary artery disease.
Patients with acute coronary syndromes have a more than doubled risk of recurrent coronary events within the subsequent year if they meet clinical criteria for familial hypercholesterolaemia, research shows.
The benefits of statin-based treatments among patients with chronic kidney disease diminish with decreasing estimated glomerular filtration rate, with little evidence of any benefit for patients on dialysis, results of a large meta-analysis show.
Patients with levels of low-density lipoprotein cholesterol normally seen in familial hypercholesterolaemia have the cardiovascular risk of someone decades older than they are, shows a population-based study.